Finnrick - Ensuring a Safer and More Transparent Supply Chain
NextGen Health

NextGen Health
Tirzepatide

Finnrick tested 2 samples of Tirzepatide (GLP-1 and GIP antagonist) from NextGen Health between 11 Jun 2025 and 29 Jun 2025. Test scores average over 7, no score below 6, and at least 2 tests warrant a tentative Finnrick Rating of A (Great).

Finnrick Rating™
A
GREAT
Tentative Rating
NextGen Health
Tirzepatide
Tested 2 Samples
Last test 29 Jun 2025

Take Action

Researcher

Request Full Data Access to the Finnrick database of peptide tests.

Free peptide testing

Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.

All Tirzepatide tests from NextGen Health

Samples are tested in commercial labs

Tests Count

2

Scores

AVG7.1MIN6.5MAX7.8

Last

29 Jun 2025

First

11 Jun 2025
Quantity
Test DateCertificate
Test Score
LabelTestedDifferencePurityBatch IDContainerTested AtSent By
29 Jun 2025View6.530mg27.300mg-9.0%99.80%(no batch ID)No Label / Copper Crimp / Clear CapLab EPublic
11 Jun 2025View7.820mg19.200mg-4.0%99.81%(no batch ID)No Label / Silver Crimp / Grey Cap Lab EPublic